Cartesian Therapeutics, Inc. (RNAC) earnings
RNAC earnings moved a median of -1.29% by the close. Quarterly and annual RNAC reports and results, each read against the price at its own news timestamp. Back to the RNAC overview →
22 measured RNAC earnings events.
Where these RNAC earnings landedvs 22 measured RNAC earnings reactions
| Middle 50% of RNAC earnings reactions | -5.34% to +1.56% |
|---|---|
| Median reaction (to close) | -1.29% |
| Measured reactions | 22 |
Point-in-time · zero look-ahead
Half of the 22 RNAC earnings events with a measured close landed between -5.34% and +1.56%; 41% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Cartesian Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update | Press release | +0.07% | -1.02% | |
| Form 10-Q Cartesian Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +0.07% | -1.02% | |
| Cartesian Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | Press release | +0.00% | +3.30% | |
| Form 10-Q Cartesian Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | +3.30% | |
| Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027 | Press release | -3.01% | -6.11% | |
| Cartesian Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Press release | +0.00% | -2.96% | |
| Form 10-Q Cartesian Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.00% | -2.96% | |
| Form 10-K Cartesian Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +4.58% | +37.71% | |
| Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | Press release | +17.98% | +26.25% | |
| Form 10-Q Cartesian Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +17.98% | +26.25% | |
| Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Press release | +0.00% | -7.95% | |
| Form 10-Q Cartesian Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | +0.00% | -7.95% | |
| Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update | Press release | +3.80% | +1.56% | |
| Form 10-Q Cartesian Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +3.80% | +1.56% | |
| Form 10-K Cartesian Therapeutics, For: Dec 31 | SEC filing · Form 10-K | +0.41% | -3.04% | |
| Cartesian Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | Press release | +1.85% | -1.56% | |
| Form 10-Q Cartesian Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | +1.85% | -1.56% | |
| Cartesian Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | Press release | -3.53% | -14.20% | |
| Form 10-Q Cartesian Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | -3.53% | -14.20% | |
| Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update | Press release | +0.22% | +1.09% | |
| Form 10-Q Cartesian Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | +0.22% | +1.09% | |
| Form 10-K Cartesian Therapeutics, For: Dec 31 | SEC filing · Form 10-K | -2.05% | -8.49% |
Keep exploring
More RNAC: analyst actions → · SEC filings → · RNAC overview →